Growth Metrics

Incyte (INCY) Profit After Tax (QoQ) (2010 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn
7 Evaxion A 64.16 Bn 64.14 Bn -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn
10 Incyte 19.28 Bn 15.27 Bn 1.17 Bn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 1.35%
Dec 31, 2025 -29.44%
Sep 30, 2025 4.73%
Jun 30, 2025 156.00%
Mar 31, 2025 -21.37%
Dec 31, 2024 89.01%
Sep 30, 2024 123.94%
Jun 30, 2024 -362.23%
Mar 31, 2024 -15.68%
Dec 31, 2023 17.41%
Sep 30, 2023 -15.86%
Jun 30, 2023 837.88%
Mar 31, 2023 -23.74%
Dec 31, 2022 -74.76%
Sep 30, 2022 -30.14%
Jun 30, 2022 324.91%
Mar 31, 2022 -93.26%
Dec 31, 2021 210.25%
Sep 30, 2021 21.60%
Jun 30, 2021 179.17%
Mar 31, 2021 -64.27%
Dec 31, 2020 1,085.66%
Sep 30, 2020 -105.24%
Jun 30, 2020 140.28%
Mar 31, 2020 -749.20%
Dec 31, 2019 -13.46%
Sep 30, 2019 21.79%
Jun 30, 2019 2.94%
Mar 31, 2019 48.14%
Dec 31, 2018 136.71%
Sep 30, 2018 -44.31%
Jun 30, 2018 227.36%
Mar 31, 2018 72.51%
Dec 31, 2017 -515.01%
Sep 30, 2017 388.80%
Jun 30, 2017 93.33%
Mar 31, 2017 -191.21%
Dec 31, 2016 824.81%
Sep 30, 2016 -182.21%
Jun 30, 2016 208.25%
Mar 31, 2016 -103.85%
Dec 31, 2015 -19.08%
Sep 30, 2015 67.57%
Jun 30, 2015 -120.06%
Mar 31, 2015 50.30%
Dec 31, 2014 -162.31%
Sep 30, 2014 260.80%
Jun 30, 2014 -8.59%
Mar 31, 2014 20.79%
Dec 31, 2013 -94.54%
Sep 30, 2013 -757.14%
Jun 30, 2013 83.59%
Mar 31, 2013 -183.44%
Dec 31, 2012 186.50%
Sep 30, 2012 -637.78%
Jun 30, 2012 108.89%
Mar 31, 2012 17.53%
Dec 31, 2011 -3.77%
Sep 30, 2011 -2.33%
Jun 30, 2011 -95.65%
Mar 31, 2011 -181.47%
Dec 31, 2010 202.65%
Sep 30, 2010 -1,141.43%
Jun 30, 2010 108.52%